Citius Oncology Secures $36.5M Financing for Commercialization of FDA-Approved Cancer Therapy
Citius Oncology has raised up to $36.5 million through a mix of debt and equity financing, including a $25 million term loan from Avenue Venture Opportunities Fund II and warrant exercises expected to yield an additional $11.5 million. The funds will support the commercialization of Lymphir (denileukin diftitox-cxdl), an FDA-approved treatment for cutaneous T-cell lymphoma.
Tickers: $CTOR
Topics: biotech commercialization funding